Abstract: Provided are a single-domain antibody against human programmed death-ligand 1 (PD-L1) and application thereof. The PD-L1 binding molecule of the present invention can be used for treating and/or preventing, or diagnosing PD-L1 related diseases such as tumors.

Abstract: An anti-IL5 nanoantibody, and a coding sequence for coding the anti-IL5 nanoantibody, a corresponding expression vector, a host cell capable of expressing the anti-IL5 nanoantibody, and a method for producing the anti-IL5 nanoantibody are provided. The nanoantibody can specifically recognize IL5 from humans and cynomolgus monkeys, does not recognize IL5 from mice, and has a good binding activity. The nanoantibody has a good IL5/IL5R blocking activity. The blocking activity is obviously superior to that of a control antibody Nucala. The nanoantibody can effectively inhibit the proliferation of TF-1 cells induced by IL5, and the inhibition activity thereof is superior to that of the control antibody Nucala. The expression yield of the nanoantibody in Pichia pastoris can reach 13 g/L, and the purity of target protein expressed in the supernatant is high.

Abstract: Disclosed is an anti-IL-4R single-domain antibody and the use thereof. In particular, disclosed are a IL-4R single-domain antibody and a VHH chain thereof, a coding sequence encoding the above-mentioned single-domain antibody or the VHH chain thereof, a corresponding expression vector, host cells capable of expressing the single-domain antibody, and a method for producing the single-domain antibody. The single-domain antibody can specifically recognize human and marmoset IL-4R, but does not recognize mouse IL-4R, and the specificity is good; the single-domain antibody can effectively inhibit the proliferation of TF-1 cells and the activation of a pSTAT6 signaling pathway in cells.

Abstract: An anti-VEGF single-domain antibody and a VHH chain thereof have been described. A coding sequence for coding the single-domain antibody or the VHH chain thereof, a corresponding expression vector, a host cell capable of expressing the single-domain antibody, and a production method for the single-domain antibody have been presented. The single-domain antibody can specifically recognize human VEGFA and will not cause cross reactions with VEGFB, VEGFC and VEGFD, thus having a good specificity. The single-domain antibody can further recognize VEGFAs of a human, a rat, a rabbit and a monkey, effectively blocks interactions between VEGFA and VEGFR2 and between VEGFA and VEGFR1, has an excellent inhibiting effect on angiogenesis, and has a good stability in a non-preparation condition.

Abstract: Provided are a single-domain antibody against human programmed death-ligand 1 (PD-L1) and application thereof. The PD-L1 binding molecule of the present invention can be used for treating and/or preventing, or diagnosing PD-L1 related diseases such as tumors.